VANCOUVER, BC – October 7, 2025 – TheNewswire - Dova Health Intelligence Inc., a leader in AI-driven gastrointestinal disease assessment, is pleased to announce a collaboration with Mayo Clinic to advance the development and validation of DovaVision UC Mayo Endoscopic Score (MES), an artificial intelligence tool designed for more precise and reproducible scoring of ulcerative colitis disease activity from colonoscopy videos.
Evaluating mucosal healing accurately is a critical element in the management of inflammatory bowel disease (IBD) and in clinical research. DovaVision UC MES applies computer vision and deep learning to standardize scoring and reduce variability in assessment, supporting informed decision-making for physicians and researchers.
Through this collaboration, Dova and Mayo Clinic will conduct joint regulatory preparation to bring DovaVision UC MES to clinical and research use. The collaboration seeks to refine the product for seamless integration into gastroenterology workflows and to prepare for FDA regulatory clearance.
“We are excited to work with Dova, an industry leader in the development of AI-enabled digital health solutions for the assessment of GI diseases, to validate DovaVision UC for the automated scoring of the Mayo Endoscopic Score, which will have applications in clinical care and research in patients with ulcerative colitis,” said Dr. Darrell Pardi, Chair of the Division of Gastroenterology and Hepatology and Professor of Medicine at Mayo Clinic Rochester.
“We are honored to collaborate with Mayo Clinic, whose leadership in IBD care and research is globally recognized,” said Solveig Johannessen, CEO of Dova Health Intelligence. “By combining Dova’s AI expertise with Mayo Clinic’s clinical excellence, we aim to deliver a tool that not only raises the standard for endoscopic assessment in ulcerative colitis but also accelerates innovation in trial design and everyday patient care.”
“Working in this rapidly developing domain is exciting, and with the combined forces of our team and the clinical group, we aim to set new standards in the digital assessment of inflammatory bowel disease,” said Dr. Michael Byrne, Chairman and Founder of Dova, and Clinical Professor of Medicine in Vancouver.
About Dova Health Intelligence
Dova Health Intelligence develops image-based AI-powered solutions to improve diagnosis, disease monitoring, and treatment decision-making in gastrointestinal medicine. Our flagship technologies include DovaVision UC MES for granular disease assessment of ulcerative colitis at scale, DovaVision BE for real-time neoplasia detection and biopsy targeting in Barrett’s esophagus, and DovaSound to support rapid, standardized intestinal ultrasound image capture and assessment. These solutions are designed in close collaboration with leading clinical institutions and a global network of key opinion leaders and gastroenterologists. For more information, visit www.dovahealth.ca.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
Click Image To View Full Size
Copyright (c) 2025 TheNewswire - All rights reserved.
